Loss of response after first-line biologic therapy in patients with inflammatory bowel disease: practical approach and management

被引：0
|
作者：
Busacca, A. [1 ]
Scrivo, B. [1 ]
Giuffrida, E. [1 ]
Guida, L. [1 ]
Carrozza, L. [1 ]
Calvaruso, V. [1 ]
Cappello, M. [1 ]
机构：
[1] Univ Palermo, Gastroenterol & Hepatol Sect, PROMISE, Palermo, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P293
引用
收藏
页码：S299 / S299
页数：1
相关论文
共 50 条
  • [1] A Practical Review on When and How to Select First-Line Biologic Therapy in Patients with Inflammatory Bowel Disease
    Frasca, Joseph D.
    Cheifetz, Adam S.
    PRACTICAL GASTROENTEROLOGY, 2020, 44 (08) : 32 - 43
  • [2] LOSS OF RESPONSE AFTER FIRST LINE ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PRATICAL APPROACH AND MANAGEMENT
    Guella, S.
    Scrivo, B.
    Calvaruso, V.
    Giuffrida, E.
    Busacca, A.
    Guida, L.
    Carrozza, L.
    Cappello, M.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S136 - S136
  • [3] Trends in choice of first-line biologic therapy for patients with inflammatory bowel disease: An observational cohort study
    Fernando, S.
    Abu-Rgeef, R.
    Menon, S.
    So, K.
    Venugopal, K.
    Picardo, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 143 - 144
  • [4] More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease
    Kakiuchi, Toshihiko
    Yoshiura, Masato
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (02) : 298 - 299
  • [5] Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK
    Akbar, Ayesha
    Orchard, Tim
    Powell, Nick
    Selinger, Christian
    Tibbatts, Clare
    FRONTLINE GASTROENTEROLOGY, 2022, 13 (06) : 490 - 496
  • [6] First-Line Therapies in Inflammatory Bowel Disease
    Girardin, Marc
    Manz, Michael
    Manser, Christine
    Biedermann, Luc
    Wanner, Roger
    Frei, Pascal
    Safroneeva, Ekaterina
    Mottet, Christian
    Rogler, Gerhard
    Schoepfer, Alain M.
    DIGESTION, 2012, 86 : 6 - 10
  • [7] Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
    Argollo, Marjorie C.
    Allocca, Mariangela
    Furfaro, Federica
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (01) : 25 - 31
  • [8] First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician
    Chang S.
    Hudesman D.
    Current Gastroenterology Reports, 2020, 22 (2)
  • [9] Biologicals first-line in chronic inflammatory bowel disease? No
    Herrlinger, K.
    Stange, E. F.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (36) : 1789 - 1789
  • [10] Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
    Atay, Ali
    Cagir, Yavuz
    Ergul, Mucahit
    Ozturk, Oguz
    Durak, Muhammed Bahaddin
    Yuksel, Ilhami
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
12345